Download Free A Pharmaceutical Executives Dilemma Book in PDF and EPUB Free Download. You can read online A Pharmaceutical Executives Dilemma and write the review.

This case places the reader in the position of chief executive officer of a global pharmaceutical company facing a difficult decision. The scenario presented is reflective of an actual decision made by a global healthcare company based in the United States. The company’s research and development team believes it may have discovered the cure for a horrible illness afflicting millions of the world’s poorest people. The company’s leadership must make a decision to either pursue the drug, which future patients would be unable to pay for, or decline to pursue it based largely on economic grounds. The decision is further complicated by the company’s poor recent financial performance. The information provided in the case related to the company’s stock price performance is identical to what the company faced as it made this decision. In addition, the mission and core values provided in the case are closely based upon the company’s own. The company’s name and individuals’ names presented in the case are fictional.
A comprehensive guide to optimizing the lifecycle management of pharmaceutical brands The mounting challenges posed by cost containment policies and the prevalence of generic alternatives make optimizing the lifecycle management (LCM) of brand drugs essential for pharmaceutical companies looking to maximize the value of their products. Demonstrating how different measures can be combined to create winning strategies, Pharmaceutical Lifecycle Management: Making the Most of Each and Every Brand explores this increasingly important field to help readers understand what they can—and must—do to get the most out of their brands. Offering a truly immersive introduction to LCM options for pharmaceuticals, the book incorporates numerous real-life case studies that demonstrate successful and failed lifecycle management initiatives, explaining the key takeaway of each example. Filled with practical information on the process of actually writing and presenting an LCM plan, as well as how to link corporate, portfolio, and individual brand strategies, the book also offers a look ahead to predict which LCM strategies will continue to be effective in the future. While the development of new drugs designed to address unmet patient needs remains the single most important goal of any pharmaceutical company, effective LCM is invaluable for getting the greatest possible value from existing brands. Pharmaceutical Lifecycle Management walks you through the process step by step, making it indispensable reading for pharmaceutical executives and managers, as well as anyone working in the fields of drug research, development, and regulation.
Drawing on a lifetime of experience, Roger Dobbah gives readers an in-depth view of R&D survival strategies and tactics and demonstrates how to apply them to any organization. The author provides insights into the role of R&D, the crucial topic of creativity and innovation, and the differences and similarities between general management and R&D man
First published in 1984, this book examines corporate crime in the pharmaceutical industry. Based on extensive research, including interviews with 131 senior executives of pharmaceutical companies in the United States, the United Kingdom, Australia, Mexico and Guatemala, the book is a major study of white-collar crime. Written in the 1980s, it covers topics such as international bribery and corruption, fraud in the testing of drugs and criminal negligence in the unsafe manufacturing of drugs. The author considers the implications of his findings for a range of strategies to control corporate crime, nationally and internationally.
Collaborations of physicians and researchers with industry can provide valuable benefits to society, particularly in the translation of basic scientific discoveries to new therapies and products. Recent reports and news stories have, however, documented disturbing examples of relationships and practices that put at risk the integrity of medical research, the objectivity of professional education, the quality of patient care, the soundness of clinical practice guidelines, and the public's trust in medicine. Conflict of Interest in Medical Research, Education, and Practice provides a comprehensive look at conflict of interest in medicine. It offers principles to inform the design of policies to identify, limit, and manage conflicts of interest without damaging constructive collaboration with industry. It calls for both short-term actions and long-term commitments by institutions and individuals, including leaders of academic medical centers, professional societies, patient advocacy groups, government agencies, and drug, device, and pharmaceutical companies. Failure of the medical community to take convincing action on conflicts of interest invites additional legislative or regulatory measures that may be overly broad or unduly burdensome. Conflict of Interest in Medical Research, Education, and Practice makes several recommendations for strengthening conflict of interest policies and curbing relationships that create risks with little benefit. The book will serve as an invaluable resource for individuals and organizations committed to high ethical standards in all realms of medicine.
A NEW YORK TIMES BESTSELLER New York Times 100 Notable Books of 2019 New York Public Library Best Books of 2019 Kirkus Reviews Best Health and Science Books of 2019 Science Friday Best Books of 2019 New postscript by the author From an award-winning journalist, an explosive narrative investigation of the generic drug boom that reveals fraud and life-threatening dangers on a global scale—The Jungle for pharmaceuticals Many have hailed the widespread use of generic drugs as one of the most important public-health developments of the twenty-first century. Today, almost 90 percent of our pharmaceutical market is comprised of generics, the majority of which are manufactured overseas. We have been reassured by our doctors, our pharmacists and our regulators that generic drugs are identical to their brand-name counterparts, just less expensive. But is this really true? Katherine Eban’s Bottle of Lies exposes the deceit behind generic-drug manufacturing—and the attendant risks for global health. Drawing on exclusive accounts from whistleblowers and regulators, as well as thousands of pages of confidential FDA documents, Eban reveals an industry where fraud is rampant, companies routinely falsify data, and executives circumvent almost every principle of safe manufacturing to minimize cost and maximize profit, confident in their ability to fool inspectors. Meanwhile, patients unwittingly consume medicine with unpredictable and dangerous effects. The story of generic drugs is truly global. It connects middle America to China, India, sub-Saharan Africa and Brazil, and represents the ultimate litmus test of globalization: what are the risks of moving drug manufacturing offshore, and are they worth the savings? A decade-long investigation with international sweep, high-stakes brinkmanship and big money at its core, Bottle of Lies reveals how the world’s greatest public-health innovation has become one of its most astonishing swindles.
Pharmaceutical giants have been doubling their investments in drug development, only to see new drug approvals to remain constant for the past decade. This book investigates and highlights a set of proactive strategies. The authors focus on three sources of pharmaceutical innovation: new management methods, new technologies, and new forms of internationalization. Their findings are illustrated in the case of the Swiss pharmaceutical industry, the leading exporter of pharmaceutical products in percentage of GDP, and some of its main pharmaceutical firms such as Novartis and Hoffmann-La Roche.
For more than fifty years, human resources departments have turned to HayGroup for concrete, practical advice on how to structure compensation programs. Also the authority behind leading books on compensation, HayGroup renders all others obsolete with this publication -- the new last word on compensation. The Executive Handbook on Compensation speaks directly to businesses' most important concerns, highlighting dramatic changes in the world of business over the past decade -- changes caused by the globalization of the economy, the diversification of the workforce, new work habits including flexible time and telecommuting, and organizational shifts that require that compensation packages maximize employee-employer partnerships like never before. The Executive Handbook on Compensation shows managers how to: -- Reward and retain key people -- Determine affordable, appropriate pay scales -- Evaluate employee expectations and boost morale -- Develop nontraditional and contingency-based compensation -- Use the latest electronic media to improve the way businesses document, evaluate, price, and plan jobs
Leadership, as a way of focusing and motivating a group or organization to achieve its aims, is a much discussed but often misunderstood concept. This comprehensive textbook introduces the subject for Masters level students. Building on the success of the first edition, this text utilises an easy to follow, map-based approach to take the reader on a journey through the various fundamental dilemmas apparent within leadership studies, dilemmas such as: Is a leader born or made? How are tensions between ethical dilemmas and economic self-interest resolved? How does a leader's desire for control balance with the need to empower members of the organization? Student-friendly features new to this edition include a wealth of leadership cases, videos and web-based content regularly updated, so that the book can be studied in the context of the most pressing contemporary leadership issues.